The role of Clinical Research in providing Evidence of Clinical Utility and Effectiveness

High-quality research is what’s needed to solve skin and wound challenges. This is a fantastic opportunity for our industry partners to gain more knowledge of Clinical Trials Research.


The Wounds Research Network comprises multi-disciplinary researchers and their aim is to provide a platform for cross-specialty, inter-disciplinary shared learning and support for the design, conduct and delivery of wound prevention and treatment research throughout the UK.

The WReN scientific committee would like to support industry colleagues by sharing current best evidence of clinical research methods which underpin clinical utility and clinical effectiveness evidence. They have expertise in mixed methods research from 1st in man to large scale randomised controlled trials in areas including intervention development, measurement of outcomes, feasibility, cohort and RCTs.

Part 1 Introduction to Clinical Research

Using examples from the wound prevention/wound treatment field the interactive training will aim to introduce:

  • Types of research evidence – from bench to bedside
  • Appraising levels of evidence eg quality aspects in the design and interpretation of clinical research including case studies, cohorts, early phase evaluation, feasibility, health economic modelling, implementation research, quality improvement methods.
  • Defining research questions to direct appropriate research methods
  • Major sources of bias and issues of generalisability.

 Part 2 Principles of Randomised Controlled Trials

Using examples of high quality clinical trials in the wound prevention/treatment field, the interactive training aims to introduce:

  • important principles in trial design and trial conduct issues including randomization, blinding and defining the analysis population
  • balancing design factors which minimize bias but impact generalisability
  • minimizing types of bias (eg selection, allocation, performance, detection, attrition and publication)
  • common trial designs
  • international standards in the reporting of clinical trials – the CONSORT statement

There will be 5 sessions as follows

Session 1 Trial designs

  • Early and late phase trials
  • Overview phase 3 trial designs – eg parallel group, crossover, factorial, cluster, adaptive (sequential, MAMS, platform)

Session 2 Key features of phase 3 effectiveness trials

  • Defining the research question
  • Why do we need control groups?
  • Why do we need randomization?
  • Common randomization methods

Session 3 Promoting generalizability, minimizing bias and harm

  • Population
  • Interventions
  • Comparator
  • Outcomes
  • CONSORT checklist

Session 4 Minimising error

  • Types of error
  • Why do we need sample size estimates?

Session 5 Participant (CONSORT) flow

  • Screening and consent
  • Attrition bias
  • Analysis populations (intention to treat verses per protocol)

Learning Outcomes

  • Identify important clinical research design features
  • Identify major sources of bias in research protocols and research evidence
  • Relate important clinical research design features to interpretation and messaging


Keynote Speakers

Prof. Jane Nixon MBE, PhD, RGN, SoTV Trustee and Professor of Tissue Viability and Clinical Trials Research, Leeds Institute Health Sciences, School of Medicine, University of Leeds

Jane Nixon

Professor of Tissue Viability and Clinical Trials Research

Leeds Institute Health Sciences, School of Medicine, University of Leeds

Read more…